Search Results
Your search for Staff matches 7294 pages
Showing 4851 - 4900Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers
A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...
GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
American Cancer Society Report Identifies Critical Gaps and Research Opportunities for Improved Cancer Care
A new report found that despite progress in the decline of cancer mortality, there are still critical gaps, including the need to develop better tools and explore research opportunities that would lead to limiting cancer as a major health concern. This blueprint article completes an eight-part...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
NIH RADx-rad Grants Support Investigation of Novel COVID-19 Testing and Surveillance Approaches
The National Institutes of Health (NIH) has awarded over $107 million to support new, nontraditional approaches and reimagined uses of existing tools to address gaps in COVID-19 testing and surveillance. The program will also develop platforms that can be deployed in future outbreaks of COVID-19...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Roswell Park Experts Named to Highly Cited Researchers List
Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...
Susan E. Hankinson, ScD, MPH, Receives AACR Distinguished Lectureship in Breast Cancer Research Award
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) honored Susan E. Hankinson, ScD, MPH, for her significant contributions to breast cancer research. Dr. Hankinson received the 2020 AACR Distinguished Lectureship in Breast Cancer Research award...
Northwell Invests $6M in Comprehensive Cancer Center in Riverhead, New York
Northwell Health recently announced that it will open a $6.2 million, 11,300-square-foot comprehensive cancer center in Riverhead, New York, by the end of this year. The new facility will provide residents of the East End of Long Island access to integrated cancer services in a conveniently located ...
John Ryan, JD, Named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan, JD, as its Senior Vice President, General Counsel, and Chief Governance Officer. Mr. Ryan has extensive expertise representing health-care and life sciences organizations in public company and nonprofit settings. He has managed a wide range of...
Two Leading Institutions Collaborate to Advance Treatment of Smoldering Multiple Myeloma
The Multiple Myeloma Research Foundation (MMRF) and Dana-Farber Cancer Institute have jointly announced a pioneering research collaboration in smoldering myeloma, a precursor disease to multiple myeloma. Combining the strengths of the MMRF, a leader in multiple myeloma data generation, and...
FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC
On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal
The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...
City of Hope Physician Joins Carol Emmott Fellowship
Lorna Rodriguez-Rodriguez, MD, PhD, Vice Chair of Faculty Development at City of Hope, is among 21 women leaders in the nation who were invited to join the Carol Emmott Fellowship Class of 2021, a 14-month program for “exceptional, innovative women leaders who are making lasting change in their...
2020 Basser Global Prize Awarded to Bella Kaufman, MD, of Israel’s Sheba Medical Center
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania recently announced Bella Kaufman, MD, of the Sheba Medical Center in Tel-Hashomer, Israel, as the recipient of the eighth annual Basser Global Prize. Dr. Kaufman is Director of the Breast Oncology Institute,...
Rutgers Researcher Receives $400K Grant to Examine Racial Health Disparities in Cancer Care
Anita Kinney, PhD, MSN, Professor at the Rutgers School of Public Health and Associate Director for Population Science and Community Outreach at Rutgers Cancer Institute of New Jersey, is among 10 recipients across the nation of an American Cancer Society and Pfizer community grant of $399,892 to...
ASH Recognizes Choosing Wisely Champions at Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions, practitioners working to tackle overuse of hematology tests and treatments, at the all-virtual 2020 ASH Annual Meeting & Exposition. Choosing Wisely, a program of the ABIM Foundation and Consumer Reports, aims...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Edith Mitchell, MD, Elected to Fellowship in the Royal College of Physicians of London
Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center–Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London (RCP). The RCP was founded in 1518 by a Royal Charter from King Henry VIII. RCP...
Welela Tereffe, MD, MPH, Named Chief Medical Executive at MD Anderson
The University of Texas MD Anderson Cancer Center has named Welela Tereffe, MD, MPH, as Chief Medical Executive. Recognized as a patient-centered and institutionally minded leader, Dr. Tereffe will assume this new position and join the institution’s executive leadership team on January 1, 2021....
ASH Announces Donation of Next-Generation Sequencing Equipment to Countries in the International Consortium
The American Society of Hematology (ASH) recently announced the donation of next-generation sequencing equipment to six reference laboratories in five countries in Latin America. These countries constitute the International Consortium on Acute Leukemia (ICAL), a clinical network supported by the...
Fan Therapy May Relieve Breathlessness Associated With Advanced Cancers
Blowing air from a fan into the face of patients with advanced cancer experiencing breathlessness—and other nonpharmacologic interventions—may offer symptomatic relief, according to new research directed by Johns Hopkins Kimmel Cancer Center investigators and published in JAMA Oncology.1 In...
Life and Death Under COVID-19
Victoria was a 79-year-old woman living alone in a London suburb. Having no children of her own, she visited us regularly here in the United States. She was one of three sisters and my sister-in-law. I knew her for more than 50 years, and she always reminded me of Audrey Hepburn, both in looks and ...
Stephanie Halene, MD, PhD, Appointed Chief of Hematology at Yale Cancer Center and Smilow Cancer Hospital
Following an extensive national search, Stephanie Halene, MD, PhD, has been appointed Chief of Hematology at Yale Cancer Center, Smilow Cancer Hospital, and the Yale School of Medicine Department of Internal Medicine. “Dr. Halene has served with distinction as Interim Chief, leading the section...
2020 FDA Approvals of Drugs for Cancer Treatment
Over the past year (January to December 2020), the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in oncology and hematology. A brief review of new approvals appears here. For complete prescribing information for ...
Roy S. Herbst, MD, PhD, Named ACCC 2020 Clinical Research Award Winner
The Association of Community Cancer Centers (ACCC) has announced the recipient of the ACCC 2020 Clinical Research Award: Roy S. Herbst, MD, PhD, Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at the Yale Cancer...
FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The FDA granted selinexor accelerated...
FDA Approves First Oral Hormone Therapy for Treating Advanced Prostate Cancer
Today, the U.S. Food and Drug Administration (FDA) approved relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. “Today’s approval marks the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require...
FDA Approves Rituximab-arrx, a Biosimilar to Rituximab
On December 17, the U.S. Food and Drug Administration (FDA) approved rituximab-arrx (Riabni), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener's granulomatosis), and...
Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy
Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive, HER2-negative primary breast cancer who are at high risk for relapse after neoadjuvant...
Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate...
ESMO Immuno-Oncology 2020: First-Line Anti–PD-1 Therapy vs BRAF/MEK Inhibition for Advanced BRAF V600–Mutated Melanoma
Findings from a propensity-matched survival analysis presented by van Breeschoten et al at the European Society for Medical Oncology (ESMO) Immuno-Oncology Virtual Congress 2020 (Abstract 37P) suggest that patients with advanced melanoma and a BRAF V600 mutation derive an enhanced survival benefit...
Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat
Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant advanced HR-positive, HER2-negative breast cancer (Abstract GS4-02).
ESMO Immuno-Oncology 2020: Sintilimab vs Docetaxel for Advanced Squamous NSCLC
Sintilimab provided superior clinical benefit compared to docetaxel in patients with previously treated, advanced and/or metastatic squamous non–small cell lung cancer (NSCLC), according to phase III study findings presented by Shi et al at the European Society for Medical Oncology (ESMO)...
FDA Approves Margetuximab-cmkb Plus Chemotherapy for Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
On December 16, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for...
Nitin Jain, MD, on B-Cell ALL: Expert Perspective on Key CAR T-Cell Treatment Advances
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, reviews six important abstracts on CAR T-cell treatments for B-cell acute lymphoblastic leukemia (ALL): successful 24-hour manufacture of CAR T-cell therapy; ALLCAR19, a novel fast-off rate therapy; donor-derived CD19-targeted...
Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with...
Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).
Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s...
Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success
Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and predict chemotherapy...
Reducing the Risk of Lymphedema in Patients With Cancer
Although the exact incidence of treatment-related lymphedema among cancer survivors is unknown—most likely due to its prolonged latency period—it can be a lifelong chronic side effect that negatively impacts survivors’ quality of life. Although the condition is often linked to treatment for breast...
ESMO Immuno-Oncology 2020: Tebentafusp Shows Activity in Metastatic Uveal Melanoma
Tebentafusp is a novel bispecific molecule consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target gp100-positive cells. The agent showed clinical benefit, including target lesion reduction, in patients with metastatic uveal melanoma,...
Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment
Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant therapy approach in patients with intermediate- or high-risk luminal early breast cancer (Abstract...
Farhad Ravandi, MD, on AML: Novel Combination Therapies for Newly Diagnosed Disease
Farhad Ravandi, MD, of The University of Texas MD Anderson Cancer Center, offers his expert perspective on key treatment studies in acute myeloid leukemia on the use of gilteritinib, consolidation chemotherapy, venetoclax, cladribine, azacitidine, quizartinib, decitabine, and CPX-351 (Session 616...
Jorge E. Cortes, MD, on CML: Expert Perspective on Key ASH Abstracts
Jorge E. Cortes, MD, of the Georgia Cancer Center at Augusta University, reviews four important studies of treatment advances in chronic myeloid leukemia (CML): nilotinib vs dasatinib in newly diagnosed disease; final 5-year results from the BFORE trial on bosutinib vs imatinib for chronic phase...
Hassan Awada, MD, on AML and Machine Learning: Improving Prognostication
Hassan Awada, MD, of the Taussig Cancer Institute, Cleveland Clinic Foundation, discusses the use of newer machine-learning techniques to help decipher a set of prognostic subgroups that could predict survival, thus potentially improving on traditional methods and moving acute myeloid leukemia into ...
ESMO Immuno-Oncology 2020: Adjuvant Atezoliumab for Patients With Muscle-Invasive Urothelial Cancer and Presence of Postsurgical ctDNA
Patients with muscle-invasive urothelial cancer and postsurgical circulating tumor DNA (ctDNA) positivity have high risk of disease recurrence following cystectomy and experienced improved clinical outcomes with adjuvant atezolizumab as compared to patients undergoing observation. These...
FDA Authorizes Antigen Test as First Over-the-Counter, Fully At-Home Diagnostic Test for COVID-19
On December 15, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first over-the-counter, fully at-home diagnostic test for COVID-19. The Ellume COVID-19 Home Test is a rapid, lateral-flow antigen test, a type of test that runs a liquid sample along a...
Trends in AYA Cancer Incidence in the United States Over 4 Decades
Cancer cases in adolescents and young adults (AYAs) have risen by 30% during the past 4 decades, with rates of kidney cancer increasing at the greatest rate, according to findings published by Scott et al in JAMA Network Open. The team said further research into screening, diagnosis, and treatment...
